Molecular docking analysis of glycogen phosphorylase with inhibitors from Cissampelos pareira Linn.

Kirubhanand Chandrashekar

doi:10.6026/97320630017866

Abstract

Cissampelos pareira Linn. is a climbing herb known in Indian traditional medicine as laghupatha. It belongs to the Menispermaceae family. The enzyme glycogen phosphorylase (GP) is a promising target for the treatment of type-2 diabetes (T2DM). A variety of natural product inhibitors with both pharmaceutical and nutraceutical potential have been reported in the search for powerful, selective and drug-like GP inhibitors that could lead to hypoglycemic medicines. Therefore, it is of interest to document the molecular docking analysis data of glycogen phosphorylase with compounds from Cissampelos pareira Linn. We report the optimal binding features of 4 compounds namely Trans-N-feruloyltyramine, Coclaurine, Magnoflorine, and Curine with the target protein for further consideration in the context of T2DM.

Highlights

Diabetes is a metabolic condition that affects hundreds of millions of people around the world
Using the Glycogen phosphorylase (GP) as a target, the identification of safe and efficacious natural compounds with the ability to help regulate blood glucose levels could lead to nonprescription nutraceutical options [7]
Cissampelos pareira, a well-known medicinal climber-plant belonging to the Menispermaceae family, has long been utilized in traditional medicine

Summary

Background

Diabetes is a metabolic condition that affects hundreds of millions of people around the world. Type-2 diabetes mellitus (T2DM) is characterized by decreased insulin secretion by the Islets of Langerhans cells and insulin resistance [1]. This leads to hyperglycemia, delayed or impaired wound healing, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and other complications [2]. Glycogen phosphorylase (GP) is a major enzyme in the glycogenolysis pathway that catalyzes glycogen breakdown to glucose-1-phosphate (Glc-1-P). It is a desirable target for the development of hypoglycemic drugs [3].

Materials and Methods

Results and Discussion

Conclusion